2020 Cerebral Palsy Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Cerebral Palsy pipeline report presents a comprehensive overview of the research and development of Cerebral Palsy drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Four drugs in Pre-clinical phase, and two drugs in Phase 3
As of February 2020, the Cerebral Palsy pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Cerebral Palsy treatment. Diverse types of targeted therapies are being explored through clinical trials including SNAP-25 (synaptosomal associated protein) inhibitor; Vesicular monoamine transporter 2 inhibitors.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Cerebral Palsy drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Cerebral Palsy pipeline drugs profiled in the report include- Cyto-012, HB-adMSC, K128, UMC-11910, onabotulinumtoxinA , TEV-50717 (deutetrabenazine), BX-U007
As of February 2020, the Cerebral Palsy pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Cerebral Palsy treatment. Diverse types of targeted therapies are being explored through clinical trials including SNAP-25 (synaptosomal associated protein) inhibitor; Vesicular monoamine transporter 2 inhibitors.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Cerebral Palsy drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Cerebral Palsy development
- Cerebral Palsy pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Cerebral Palsy pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Cerebral Palsy pipeline candidates included
- Business overview and snapshot of all companies involved in Cerebral Palsy pipeline are included
- Latest market and pipeline developments are provided in the report
Cerebral Palsy pipeline drugs profiled in the report include- Cyto-012, HB-adMSC, K128, UMC-11910, onabotulinumtoxinA , TEV-50717 (deutetrabenazine), BX-U007
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Cerebral Palsy Condition
2.3 Cerebral Palsy Pipeline Snapshot, 2020
2.4 Companies investing in Cerebral Palsy pipeline therapeutics
2.5 Phase wise Cerebral Palsy Pipeline Candidates
2.6 Most Researched Mechanism of Action of Cerebral Palsy Pipeline Products
2.7 Route of Administration of Cerebral Palsy Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Baylx Inc Overview, Contacts and ASD Pipeline Drugs
3.2 CytoDel Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Hope Biosciences LLC Overview, Contacts and ASD Pipeline Drugs
3.4 Kashiv BioSciences LLC Overview, Contacts and ASD Pipeline Drugs
3.5 Meridigen Biotech Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 Mylan NV Overview, Contacts and ASD Pipeline Drugs
3.7 Teva Pharmaceutical Industries Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 Cyto-012 Drug Details
4.1.1 Cyto-012 Current Status
4.1.2 Cyto-012 Drug Overview
4.1.3 Cyto-012 Mechanism of Action
4.1.4 Cyto-012 Licensing/Collaboration Companies
4.1.5 Cyto-012 Clinical Trials
4.2 HB-adMSC Drug Details
4.2.1 HB-adMSC Current Status
4.2.2 HB-adMSC Drug Overview
4.2.3 HB-adMSC Mechanism of Action
4.2.4 HB-adMSC Licensing/Collaboration Companies
4.2.5 HB-adMSC Clinical Trials
4.3 K128 Drug Details
4.3.1 K128 Current Status
4.3.2 K128 Drug Overview
4.3.3 K128 Mechanism of Action
4.3.4 K128 Licensing/Collaboration Companies
4.3.5 K128 Clinical Trials
4.4 UMC-11910 Drug Details
4.4.1 UMC-11910 Current Status
4.4.2 UMC-11910 Drug Overview
4.4.3 UMC-11910 Mechanism of Action
4.4.4 UMC-11910 Licensing/Collaboration Companies
4.4.5 UMC-11910 Clinical Trials
4.5 onabotulinumtoxinA Drug Details
4.5.1 onabotulinumtoxinA Current Status
4.5.2 onabotulinumtoxinA Drug Overview
4.5.3 onabotulinumtoxinA Mechanism of Action
4.5.4 onabotulinumtoxinA Licensing/Collaboration Companies
4.5.5 onabotulinumtoxinA Clinical Trials
4.6 TEV-50717 (deutetrabenazine) Drug Details
4.6.1 TEV-50717 (deutetrabenazine) Current Status
4.6.2 TEV-50717 (deutetrabenazine) Drug Overview
4.6.3 TEV-50717 (deutetrabenazine) Mechanism of Action
4.6.4 TEV-50717 (deutetrabenazine) Licensing/Collaboration Companies
4.6.5 TEV-50717 (deutetrabenazine) Clinical Trials
4.7 BX-U007 Drug Details
4.7.1 BX-U007 Current Status
4.7.2 BX-U007 Drug Overview
4.7.3 BX-U007 Mechanism of Action
4.7.4 BX-U007 Licensing/Collaboration Companies
4.7.5 BX-U007 Clinical Trials
5. LATEST CEREBRAL PALSY PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Cerebral Palsy Condition
2.3 Cerebral Palsy Pipeline Snapshot, 2020
2.4 Companies investing in Cerebral Palsy pipeline therapeutics
2.5 Phase wise Cerebral Palsy Pipeline Candidates
2.6 Most Researched Mechanism of Action of Cerebral Palsy Pipeline Products
2.7 Route of Administration of Cerebral Palsy Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Baylx Inc Overview, Contacts and ASD Pipeline Drugs
3.2 CytoDel Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Hope Biosciences LLC Overview, Contacts and ASD Pipeline Drugs
3.4 Kashiv BioSciences LLC Overview, Contacts and ASD Pipeline Drugs
3.5 Meridigen Biotech Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 Mylan NV Overview, Contacts and ASD Pipeline Drugs
3.7 Teva Pharmaceutical Industries Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 Cyto-012 Drug Details
4.1.1 Cyto-012 Current Status
4.1.2 Cyto-012 Drug Overview
4.1.3 Cyto-012 Mechanism of Action
4.1.4 Cyto-012 Licensing/Collaboration Companies
4.1.5 Cyto-012 Clinical Trials
4.2 HB-adMSC Drug Details
4.2.1 HB-adMSC Current Status
4.2.2 HB-adMSC Drug Overview
4.2.3 HB-adMSC Mechanism of Action
4.2.4 HB-adMSC Licensing/Collaboration Companies
4.2.5 HB-adMSC Clinical Trials
4.3 K128 Drug Details
4.3.1 K128 Current Status
4.3.2 K128 Drug Overview
4.3.3 K128 Mechanism of Action
4.3.4 K128 Licensing/Collaboration Companies
4.3.5 K128 Clinical Trials
4.4 UMC-11910 Drug Details
4.4.1 UMC-11910 Current Status
4.4.2 UMC-11910 Drug Overview
4.4.3 UMC-11910 Mechanism of Action
4.4.4 UMC-11910 Licensing/Collaboration Companies
4.4.5 UMC-11910 Clinical Trials
4.5 onabotulinumtoxinA Drug Details
4.5.1 onabotulinumtoxinA Current Status
4.5.2 onabotulinumtoxinA Drug Overview
4.5.3 onabotulinumtoxinA Mechanism of Action
4.5.4 onabotulinumtoxinA Licensing/Collaboration Companies
4.5.5 onabotulinumtoxinA Clinical Trials
4.6 TEV-50717 (deutetrabenazine) Drug Details
4.6.1 TEV-50717 (deutetrabenazine) Current Status
4.6.2 TEV-50717 (deutetrabenazine) Drug Overview
4.6.3 TEV-50717 (deutetrabenazine) Mechanism of Action
4.6.4 TEV-50717 (deutetrabenazine) Licensing/Collaboration Companies
4.6.5 TEV-50717 (deutetrabenazine) Clinical Trials
4.7 BX-U007 Drug Details
4.7.1 BX-U007 Current Status
4.7.2 BX-U007 Drug Overview
4.7.3 BX-U007 Mechanism of Action
4.7.4 BX-U007 Licensing/Collaboration Companies
4.7.5 BX-U007 Clinical Trials
5. LATEST CEREBRAL PALSY PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
